Insilico Medicine
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $110.0Mattributed |
|---|---|
| Latest round | series-d+, $110.0M, 2025-03-01attributed |
| Founded | unknown |
| Headquarters | Cambridge MA |
| Industry | biotech|ai|drug-discovery |
| Stage | series-b+ |
| Website | insilico.com |
Insilico Medicine uses generative AI to design novel drug candidates, predict clinical trial outcomes, and accelerate hit-to-lead optimization for pharma partners and its own pipeline. Its end-to-end platform covers target discovery, molecular design, and synthesis planning, moving its lead fibrosis compound into Phase II trials.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-03-01 | series-d+ | $110.0M | undisclosed |
Detected tech stack
Tilda, reCAPTCHA, PHP, DDoS-Guard, Hammer.js
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series D+, $110.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $110.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | insilico.com, read 2026-05-05 |
| Description | self-reported | insilico.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.